ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 705,02
0,33%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Virpax Pharmaceuticals Inc (VRPX)

  7. Virpax Pharmaceuticals Inc (VRPX) Actualités

VRPX Virpax Pharmaceuticals Inc

0,6767
-0,0507 (-6,97%)
01 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Virpax Pharmaceuticals Inc VRPX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0507 -6,97% 0,6767 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,73 0,649 0,73 0,70 0,7274
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/5/202413:30BWVirpax® Pharmaceuticals to Present at 2024 BIO International..
17/5/202422:05EDGAR2Form 8-K - Current report
16/5/202422:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
15/5/202414:00BWVirpax Announces Pricing of $2.25 Million Public Offering
15/5/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
13/5/202423:30EDGAR2Form S-1/A - General form for registration of securities..
13/5/202422:20EDGAR2Form 8-K - Current report
13/5/202422:10BWVirpax Pharmaceuticals Reports 2024 First Quarter Results..
13/5/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/4/202413:30BWVirpax Announces Results of Maximum Tolerated Dose Study for..
26/3/202412:30BWVirpax Pharmaceuticals Reports 2023 Year-End Results
27/2/202413:31BWVirpax Pharmaceuticals Announces Reverse Stock Split to..
27/2/202413:30BWVirpax Pharmaceuticals Announces Proposed Settlement of..
07/2/202413:30BWVirpax Pharmaceuticals Announces Preliminary Results of..
31/1/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202313:30EDGAR2Form 8-K - Current report
29/12/202313:30BWVirpax Pharmaceuticals Announces Results of Special..
13/12/202314:30EDGAR2Form 8-K - Current report
07/12/202315:08EDGAR2Form DEF 14A - Other definitive proxy statements
07/12/202314:58EDGAR2Form 8-K - Current report
07/12/202314:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/11/202322:57EDGAR2Form PRE 14A - Other preliminary proxy statements
17/11/202313:30EDGAR2Form 8-K - Current report
17/11/202313:15EDGAR2Form 8-K - Current report
17/11/202313:10BWVirpax Pharmaceuticals Announces Notification from Nasdaq..
17/11/202313:00BW Virpax Pharmaceuticals Announces Leadership Transition
16/11/202322:51EDGAR2Form 8-K - Current report
15/11/202322:15BWVirpax Pharmaceuticals Reports 2023 Third Quarter Results..
15/11/202321:03EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
31/10/202313:58BWVirpax Pharmaceuticals Announces that Envelta™ Remains on..
12/10/202314:02BWVirpax Pharmaceuticals Announces Extension of CRADA with the..
11/10/202322:10EDGAR2Form 8-K - Current report
03/10/202315:51EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/10/202314:58BWGerald W. Bruce Appointed President and CEO of Novvae™..
27/9/202314:58BWVirpax Pharmaceuticals Announces Results of Probudur™ Dose..
26/9/202314:58BWVirpax Pharmaceuticals to Present at the LD Micro Main Event..
21/9/202319:35BWAltasciences von Virpax ausgewählt, um die Entwicklung eines..
21/9/202319:18BWAltasciences choisi par Virpax pour soutenir le..
21/9/202316:00BWAltasciences Chosen by Virpax to Support the Development of..
18/9/202313:58BWVirpax Pharmaceuticals Announces the Formation of Novvae™..
05/9/202315:28EDGAR2Form 8-K - Current report
05/9/202315:00BWVirpax Pharmaceuticals Updates on Litigation
28/8/202314:58BWVirpax® Pharmaceuticals to Present at H.C. Wainwright 25th..

Dernières Valeurs Consultées

NASDAQ
VRPX
Virpax Pharmaceuticals
COIN
COFGBP
BIT
P21TH4
NLBNPIT21TH4 20240621 1.08
LSE
KYGA
Kerry
NYSE
GGT-E
Gabelli Multimedia
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés